QT VASCULAR LTD.
(Company Registration No.: 201305911K)
(Incorporated in Republic of Singapore)
(the "Company")

RESPONSE TO QUERIES FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED REGARDING TRADING ACTIVITY

QT Vascular Ltd (the "**Company**") refers to the queries from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 31 May 2017 regarding the unusual volume movements in the Company's shares recently and wishes to respond to the queries as follows:

1. Are you (the issuer) aware of any information not previously announced concerning you, your subsidiaries or associated companies which, if known, might explain the trading? Such information may include events that are potentially material and price-sensitive, such as discussions and negotiations that may lead to joint ventures, mergers, acquisitions or purchase or sale of a significant asset. You may refer to paragraph 9 in Appendix 7A of the Catalist Rules for further examples. If yes, the information shall be announced immediately.

The Company held its annual general meeting today, the results of which are contained in a separate announcement made today.

The Company is constantly on the lookout for opportunities to create and/or unlock value for its business and shareholders through initiatives including but not limited to disposals of its assets and funding raising activities.

The Company will be holding an extraordinary general meeting on 2 June 2017 to seek shareholders' approval for the potential transaction involving the disposal of certain assets of the Company and its subsidiaries (collectively, the "**Group**") relating to the uncoated peripheral products ("**Potential Sale**"). Please refer to the notice of EGM and circular to shareholders on the same dated 18 May 2017 for more information.

In relation to the Company's negotiations for possible transaction(s) involving its coronary product(s) (as announced by the Company on 22 May 2017), the Company wishes to update that it is currently engaging with interested third parties for the potential sale of its non-drug coated coronary product, Chocolate XD®, possibly with an option to purchase the drug-coated coronary product, Chocolate Heart™ ("**Possible Coronary Transaction(s)**"). To date, the Company has not received any offers for any Potential Coronary Transaction(s) from any party.

Other than the aforesaid, the Company is not aware of any information not previously announced concerning the Group which, might explain the trading volume movements today. The Company does not have any associated companies.

Shareholders and potential investors should exercise caution when trading in the shares of the Company as there is no certainty on the completion of the Potential Sale and/or that the current negotiations relating to the Possible Coronary Transaction(s) will materialise into any definitive transaction(s). When in doubt as to the action they should take, shareholders and potential investors should consult their financial, tax or other advisors.

2. Are you aware of any other possible explanation for the trading? Such information may include public circulation of information by rumours or reports.

The Company is not aware of any possible explanation for the trading.

3. Can you confirm your compliance with the listing rules and. In particular, Catalist Rule 703?

The Company confirms that it is in compliance with the listing rules and, in particular, Catalist Rule 703.

The Board of Directors collectively and individually takes responsibility for the accuracy of the aforesaid replies to the queries raised by the SGX-ST.

BY ORDER OF THE BOARD

Eitan Konstantino
Chief Executive Officer
31 May 2017

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.
